评估接受CDK-4/6抑制剂治疗的患者在治疗方面根据人口统计学变量的差异。
Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables.
作者信息
Rajendran Sneha, Petruzzi Marina, Ren Dianxu, Bender Catherine, Brufsky Adam, Rosenzweig Margaret Q
机构信息
Department of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
School of Medicine, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, USA.
出版信息
Future Oncol. 2025 Feb;21(5):565-568. doi: 10.1080/14796694.2025.2455929. Epub 2025 Jan 26.
BACKGROUND
The accessibility and outcomes of cyclin-dependent kinase 4 and 6 inhibitors (CDKi) in metastatic breast cancer (MBC) according to demographic factors are unknown.
RESEARCH DESIGN AND METHODS
Retrospective review of patients with ER+ MBC prescribed first-line CDKi therapy from January 2015 through December 2022. Abstraction included time from CDKi prescription to drug initiation (TTI), time from CDKi initiation to progression (TTP), time from CDKi initiation to death or 6/30/2022, and variables (age, race, partner status, insurance type, BMI, number of comorbidities). Descriptive, comparative, and correlational statistics are used.
RESULTS
= 173 patients. No significant demographic differences in TTI or TTP. In the multivariate model TTI to death, patients with Medicaid insurance had significantly shorter overall survival than patients with private insurance.
CONCLUSIONS
Medicaid insurance is associated with worse outcomes of MBC therapy, not attributed to TTI delay. Personalization of support may be helpful.
背景
根据人口统计学因素，转移性乳腺癌（MBC）患者使用细胞周期蛋白依赖性激酶4和6抑制剂（CDKi）的可及性和治疗结果尚不清楚。
研究设计与方法
回顾性分析2015年1月至2022年12月接受一线CDKi治疗的雌激素受体阳性（ER+）MBC患者。提取的数据包括从开具CDKi处方到开始用药的时间（TTI）、从开始使用CDKi到疾病进展的时间（TTP）、从开始使用CDKi到死亡或到2022年6月30日的时间，以及变量（年龄、种族、伴侣状况、保险类型、体重指数、合并症数量）。使用描述性、比较性和相关性统计方法。
结果
共173例患者。TTI或TTP在人口统计学方面无显著差异。在多变量模型中，使用医疗补助保险的患者从TTI到死亡的总生存期显著短于使用私人保险的患者。
结论
医疗补助保险与MBC治疗的较差结果相关，这并非归因于TTI延迟。个性化支持可能会有所帮助。
Zotero 插件